Immuron Limited reveals key findings from NMRC study, eyes future collaboration with U.S. DoD
Immuron Limited has announced the results of a Campylobacter human infection model study conducted by the U.S. Naval Medical Research Command (NMRC). The Melbourne-based biopharmaceutical company, listed on the ASX (IMC) and NASDAQ (IMRN), focuses on developing oral immunotherapies for gut-mediated diseases, including its flagship product, Travelan. Recently, NMRC concluded an interim analysis of a […]